This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Dow Today: Travelers Companies (TRV) Leads The Day Higher, Pfizer (PFE) Lags

The Dow Jones Industrial Average (^DJI) is trading down 13.0 points at 13,200 as of Tuesday, May 1, 2012, 9:35 a.m. ET. During this time, 25.6 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 743.8 million. The NYSE advances/declines ratio sits at 1,468 issues advancing vs. 1,199 declining with 178 unchanged.

The Dow component leading the way higher looks to be Travelers Companies (NYSE:TRV), which is sporting a 38-cent gain (+0.6%) bringing the stock to $64.70. Volume for Travelers Companies currently sits at 94,538 shares traded vs. an average daily trading volume of 3.1 million shares.

Travelers Companies has a market cap of $24.9 billion and is part of the financial sector and insurance industry. Shares are up 8.7% year to date as of Monday's close. The stock's dividend yield sits at 2.9%.

The Travelers Companies, Inc., through its subsidiaries, provides various commercial and personal property and casualty insurance products and services to businesses, government units, associations, and individuals primarily in the United States. The company has a P/E ratio of 18.6, below the average insurance industry P/E ratio of 18.8 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Travelers Companies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

Holding back the Dow today is Pfizer (NYSE:PFE), which is lagging the broader Dow index with a 26-cent decline (-1.1%) bringing the stock to $22.64. This single loss is lowering the Dow Jones Industrial Average by 1.97 points or roughly accounting for 15.2% of the Dow's overall loss. Volume for Pfizer currently sits at 2.8 million shares traded vs. an average daily trading volume of 34.8 million shares.

Pfizer has a market cap of $173.96 billion and is part of the health care sector and drugs industry. Shares are up 5.8% year to date as of Monday's close. The stock's dividend yield sits at 3.8%.

Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. The company has a P/E ratio of 20.8, above the average drugs industry P/E ratio of 18 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Submit an article to us!
DOW 16,979.13 +59.54 0.35%
S&P 500 1,986.51 +4.91 0.25%
NASDAQ 4,526.4820 -1.0320 -0.02%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs